静脉注射富含IgM的免疫球蛋白治疗重症COVID-19:一项多中心倾向加权队列研究
该回顾性多中心队列研究纳入2020年5月至2021年4月德国和奥地利10个ICU的316例实验室确诊重症COVID-19患者,其中146例接受静脉IgM富集免疫球蛋白、170例未接受作为对照,主要终点为30天死亡率,采用Cox回归模型并以机器学习SuperLearner进行倾向评分加权校正。结果显示,总体队列30天死亡率无生存差异(HRadj 0.83;95%CI 0.55–1.25;p=0.374)。在免疫球蛋白治疗时未机械通气的患者中,30天生存改善未达统计学显著(HRadj 0.23;95%CI 0.05–1.08;p=0.063);在每日剂量≥15 g且疗程≥3天的亚组中,差异亦未达统计学显著(HRadj 0.65;95%CI 0.41–1.03;p=0.068)。作者认为,置信区间可能提示某些亚组存在临床相关效应,早期给药(即重症但尚未机械通气的COVID-19患者)及≥15 g/d至少3天的方案可能带来获益且无安全性担忧,但需在随机临床试验中验证。
要点
- 总体队列316例重症COVID-19 ICU患者中,IgM富集免疫球蛋白组146例 vs 对照组170例,30天死亡率无显著差异(HRadj 0.83;95%CI 0.55–1.25;p=0.374)。
- 治疗时未机械通气的患者30天生存改善未达统计学显著(HRadj 0.23;95%CI 0.05–1.08;p=0.063),作者认为早期给药(重症但尚未机械通气)可能获益。
- 每日剂量≥15 g且疗程≥3天的亚组同样未达统计学显著(HRadj 0.65;95%CI 0.41–1.03;p=0.068)。
- 作者认为该剂量与早期给药方案可能带来获益且无安全性担忧,但上述发现需在即将开展的随机临床试验中验证。
适用人群与场景
- 2020年5月至2021年4月在德国和奥地利10个ICU治疗的316例实验室确诊重症COVID-19患者。
- 其中146例接受静脉IgM富集免疫球蛋白治疗,170例未接受者作为对照。
处置流程与药物剂量
- IgM富集免疫球蛋白每日剂量≥15 g且疗程≥3天为研究分析的一个亚组方案,作者认为该剂量与至少3天疗程可能带来获益。
- 作者认为早期给药(即在重症但尚未机械通气的COVID-19患者中)可能带来获益。
研究设计与关键结果
- 研究类型:回顾性多中心队列研究;样本量316例;10个德国和奥地利ICU;人群为实验室确诊重症COVID-19;干预为静脉IgM富集免疫球蛋白(146例)vs 未接受(170例对照)。
- 主要终点30天死亡率:总体队列两组无生存差异(HRadj 0.83;95%CI 0.55–1.25;p=0.374)。
- 亚组:免疫球蛋白治疗时未机械通气的患者30天生存改善未达统计学显著(HRadj 0.23;95%CI 0.05–1.08;p=0.063)。
- 亚组:每日剂量≥15 g且疗程≥3天的患者差异未达统计学显著(HRadj 0.65;95%CI 0.41–1.03;p=0.068)。
- 协变量校正采用基于机器学习的SuperLearner进行倾向评分加权,以克服因缺乏随机化导致的选择偏倚;分析采用Cox回归模型。
证据类型、等级与局限
- 证据类型:回顾性多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管不能证明静脉IgM富集免疫球蛋白具有统计学可靠的效果,但置信区间可能提示某些亚组存在临床相关效应。
- 作者认为,早期给药(即重症但尚未机械通气的COVID-19患者)及每日剂量≥15 g、至少3天的方案可能带来获益且无安全性担忧。
- 作者指出,上述发现需在即将开展的随机临床试验中验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: A profound inflammation-mediated lung injury with long-term acute respiratory distress and high mortality is one of the major complications of critical COVID-19. Immunoglobulin M (IgM)-enriched immunoglobulins seem especially capable of mitigating the inflicted inflammatory harm. However, the efficacy of intravenous IgM-enriched preparations in critically ill patients with COVID-19 is largely unclear.
METHODS: In this retrospective multicentric cohort study, 316 patients with laboratory-confirmed critical COVID-19 were treated in ten German and Austrian ICUs between May 2020 and April 2021. The primary outcome was 30-day mortality. Analysis was performed by Cox regression models. Covariate adjustment was performed by propensity score weighting using machine learning-based SuperLearner to overcome the selection bias due to missing randomization. In addition, a subgroup analysis focusing on different treatment regimens and patient characteristics was performed.
RESULTS: Of the 316 ICU patients, 146 received IgM-enriched immunoglobulins and 170 cases did not, which served as controls. There was no survival difference between the two groups in terms of mortality at 30 days in the overall cohort (HRadj: 0.83; 95% CI: 0.55 to 1.25; p = 0.374). An improved 30-day survival in patients without mechanical ventilation at the time of the immunoglobulin treatment did not reach statistical significance (HRadj: 0.23; 95% CI: 0.05 to 1.08; p = 0.063). Also, no statistically significant difference was observed in the subgroup when a daily dose of ≥ 15 g and a duration of ≥ 3 days of IgM-enriched immunoglobulins were applied (HRadj: 0.65; 95% CI: 0.41 to 1.03; p = 0.068).
CONCLUSIONS: Although we cannot prove a statistically reliable effect of intravenous IgM-enriched immunoglobulins, the confidence intervals may suggest a clinically relevant effect in certain subgroups. Here, an early administration (i.e. in critically ill but not yet mechanically ventilated COVID-19 patients) and a dose of ≥ 15 g for at least 3 days may confer beneficial effects without concerning safety issues. However, these findings need to be validated in upcoming randomized clinical trials. Trial registration DRKS00025794 , German Clinical Trials Register, https://www.drks.de . Registered 6 July 2021.
参考来源
- Rahmel T, Kraft F, Haberl H, et al. Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study. Crit Care. 2022. PMID: 35799196. doi:10.1186/s13054-022-04059-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。